Core Viewpoint - The company XinNuoWei (300765.SZ) announced that its subsidiary, Giant Stone Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SYS6023, a HER3-targeted antibody-drug conjugate [1] Group 1 - SYS6023 is designed to target specific receptors on tumor surfaces and utilizes a topoisomerase I inhibitor developed by the company as its payload [1] - The mechanism of SYS6023 involves binding to tumor cells, entering them through endocytosis, and releasing toxins to kill cancer cells [1] - The payload of SYS6023 is not a substrate for efflux pumps, which is expected to help avoid resistance issues commonly seen with DXd class ADCs [1]

Core Viewpoint - The announcement highlights that New Horizon (新诺威) has received approval from the National Medical Products Administration for clinical trials of SYS6023, a HER3-targeted antibody-drug conjugate [2] Group 1: Product Development - SYS6023 is designed as a HER3-targeted antibody-drug conjugate that utilizes a self-developed topoisomerase I inhibitor as its payload [2] - The drug is intended to bind to specific receptors on tumor surfaces, allowing for internalization and subsequent release of toxins to kill tumor cells [2] - The payload of SYS6023 is not a substrate for efflux pumps, which is expected to help avoid resistance issues commonly seen with DXd class ADCs [2]

Group 1 - The core point of the article is that XinNuoWei (300765.SZ) announced that its subsidiary, Jushi Biotech, received approval from the National Medical Products Administration for the clinical trial of SYS6023, a HER3-targeted antibody-drug conjugate for use in patients with unresectable locally advanced or metastatic breast cancer [1] Group 2 - SYS6023 utilizes a topoisomerase I inhibitor developed by the company as its payload [1] - The approval allows the company to conduct clinical trials, which are necessary before the drug can be marketed and sold, following further regulatory approval [1] - The drug development process is characterized by high investment, high risk, and long cycles, with potential risks including underperformance in clinical trials, failure to obtain regulatory approval, delays in market launch, or lower-than-expected sales post-launch [1]

获得药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、概述 证券代码：300765 证券简称：新诺威 公告编号：2026-009 石药创新制药股份有限公司 关于控股子公司 SYS6023 抗体偶联药物 石药创新制药股份有限公司（以下简称"公司"）的控股子公司石药集团巨石 生物制药有限公司（以下简称"巨石生物"）于近日收到国家药品监督管理局核 准签发关于 SYS6023 的《药物临床试验批准通知书》，将于近期开展临床试验。 现将相关情况公告如下： 二、药物的基本信息 药物名称：SYS6023 受 理 号：CXSL2501055 申请人：石药集团巨石生物制药有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 12 月 8 日受理的 SYS6023 临床试验申请符合药品注册的有关要求，同意本品 开展在不可切除局部晚期或转移性乳腺癌的联合用药的临床试验，具体为：一项 评价 SYS6023 联合用药治疗不可切除局部晚期或转移性乳腺癌的有效性和安全 性的Ⅱ期临床研究。 三、药物的其他相关情况 SYS6023 ...

Core Viewpoint - The company Xinnoway (300765.SZ) is currently facing significant stock price volatility due to poor performance forecasts and market sentiment, with a recent stock price of 35.79 yuan reflecting a 2.40% increase on the day but a 12.66% decline over the past 20 days [1]. Group 1: Stock Performance - As of February 10, 2026, Xinnoway's stock price was reported at 35.79 yuan, with a daily increase of 2.40% [1]. - The stock has experienced a cumulative decline of 3.82% over the past 5 days and 12.66% over the past 20 days [1]. - The current price-to-earnings ratio (TTM) is negative at -458.45, indicating the company is in a loss position [1]. Group 2: Institutional Insights - Southwest Securities reported on February 8, 2026, that the A-share innovative drug sector declined by 1.32%, with Xinnoway's weekly drop reaching 12.53%, placing it among the worst performers in the sector [1]. - The overall institutional rating is neutral, with profit forecasts indicating a net profit of 54 million yuan for 2025 (a 0.51% year-on-year increase) and an expected improvement to 73 million yuan in 2026 (a 35.19% year-on-year increase) [1]. - The uncertainty surrounding the innovative drug development process remains a significant risk factor [1]. Group 3: Recent Events - On January 30, 2026, Xinnoway completed a management adjustment, promoting the former board secretary Dai Long (a post-90s executive) to general manager, with Xu Wen taking over as board secretary [2]. - On the same day, the company announced a strategic cooperation with AstraZeneca, involving an upfront payment of 1.2 billion USD, with Giant Bio receiving 35% [2]. - The market reacted cautiously to the appointment of a young executive and the performance decline, resulting in a stock price drop of 15.72% on that day [2].

Core Viewpoint - The food and beverage sector is experiencing a pullback, with the Huabao Food and Beverage ETF (515710) showing a slight decline of 0.17% as of the latest update, influenced by significant drops in key stocks like XinNuoWei and JinHuiJiu [1][3]. Group 1: Market Performance - The Huabao Food and Beverage ETF (515710) is currently trading at 0.590, reflecting a decrease of 0.001, or -0.17% [2]. - Major stocks within the sector, such as XinNuoWei, JinHuiJiu, and ShuiJingFang, have seen declines exceeding 2% and 1%, respectively, contributing to the overall negative performance of the sector [1][2]. Group 2: Industry Insights - A recent survey indicates that the demand for liquor has increased in the month leading up to the Spring Festival, with overall sales performance of major liquor distributors exceeding expectations, despite a reported decline in shipment volumes of 10%-20% [1]. - The food and beverage sector's valuation is at a historical low, with the price-to-earnings ratio of the underlying index for the Huabao ETF at 20.59, placing it in the 9.2% percentile over the past decade, suggesting a favorable long-term investment opportunity [3]. Group 3: Future Outlook - Looking ahead, improvements in supply and demand dynamics across various sub-sectors are anticipated by 2026, with a clearer recovery in the Consumer Price Index (CPI) expected, which may benefit traditional consumption sectors [3]. - The Huabao Food and Beverage ETF is positioned to track key high-end and mid-range liquor stocks, with approximately 60% of its portfolio allocated to leading liquor brands and nearly 40% to other beverage and dairy segments [3].

Group 1 - The core viewpoint of the news highlights the mixed performance of major indices, with the China Securities Food and Beverage Index declining by 1.16% as of the close on February 10, while certain stocks like Jinhe Industrial and New Noble showed gains [1] - The Tianhong Food and Beverage ETF (159736) experienced a net subscription of 8 million shares and a trading volume exceeding 24 million yuan on the same day, indicating strong investor interest [1] - The Tianhong ETF tracks the China Securities Food and Beverage Index and focuses on leading stocks in high-end and mid-range liquor, as well as other segments like beverages and condiments, with top-weighted stocks including Moutai, Wuliangye, and Yili [1] Group 2 - The news mentions that the "免单卡" (Free Order Card) can be used for purchasing New Year goods, covering a wide range of products from major supermarkets and convenience stores, indicating a shift in consumer purchasing behavior ahead of the Spring Festival [2] - Ping An Securities notes that the food and beverage sector has been performing well, with Moutai's sales recovering and prices stabilizing, as the restaurant supply chain enters a peak stocking season for the Spring Festival [2] - The current market liquidity is described as ample, and with the implementation of macro consumption policies, consumer demand is expected to continue to recover [2]

Group 1 - Seedance2.0 is expected to be a pivotal moment for AI in the film industry, particularly in the production of AI comics and short dramas, leading to significant cost reductions and efficiency improvements in content creation [2] - The release of Seedance2.0 has sparked widespread evaluation and discussion within the industry, showcasing impressive capabilities in multi-modal thinking and video generation from various input types [2] - The film and television sector saw a substantial increase, with the film industry index rising by 13.83%, significantly outperforming other sectors, driven by the excitement around AI applications [2] Group 2 - The innovative pharmaceutical sector is experiencing a resurgence, with notable stock price increases among companies such as Wanbangde and Guangshengtang, indicating renewed investor interest [3] - The National Medical Products Administration announced that by 2025, China's pharmaceutical industry will accelerate its internationalization, with cumulative overseas licensing transactions for innovative drugs expected to exceed $130 billion [3] - A strategic cooperation agreement between Shiyao Group and AstraZeneca could yield up to $18.5 billion, marking a significant milestone in the company's business development transactions [3] Group 3 - Emerging technologies remain a key focus for the market, with a recommendation to concentrate on sectors benefiting from AI applications and international expansion [4] - The recent volatility in the Chinese stock market is attributed to global financial tightening concerns and pre-holiday cautious sentiment, but there is optimism regarding the domestic economic outlook [4] - The semiconductor sales growth is projected to accelerate, with high demand for domestic chips and related industries expected to continue through 2026 [4][5]

AI应用主线热度扩散 昨日，市场焦点在AI应用主线。受Seedance视频模型火爆"出圈"的提振，"AI+影视"方向大幅领涨。以 申万二级行业划分，影视院线指数昨日收涨13.83%，涨幅远超其他行业，光线传媒、幸福蓝海、捷成 股份收获20%幅度涨停，华谊兄弟、华策影视等涨超10%。 张大伟 制图 机构观点 Seedance2.0发布或为AI影视的"奇点"时刻，有望在AI漫剧、AI短剧等短内容方面率先得到广泛应用， 进一步推动漫剧、短剧制作大幅降本提效和产能供给释放 ◎记者 费天元 2月10日，A股全天窄幅盘整，沪指日内振幅仅0.41%，为开年以来最低，同时市场量能也出现萎缩，显 示春节假期前资金面趋于平淡。 截至收盘，上证指数报4128.37点，涨0.13%；深证成指报14210.63点，涨0.02%；创业板指报3320.54 点，跌0.37%；科创综指报1802.46点，涨0.31%。沪深两市合计成交21055亿元，较前一日缩量1439亿 元。 机构：新兴科技仍是主线 从2月9日的太空光伏到昨日的AI应用，节前市场重回科技成长主线。在部分机构看来，当前，新兴科 技仍是驱动A股盈利复苏的主要动力，建议聚焦"A ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [1] Core Insights - The A-share innovative drug sector saw a decline of 1.32% this week, outperforming the CSI 300 index by 0.02 percentage points, while the biopharmaceutical sector rose by 0.04% [2][14] - The Hong Kong innovative drug sector decreased by 1.45%, outperforming the Hang Seng Index by 1.57 percentage points [19] - The XBI index in the US increased by 0.64%, with a cumulative increase of 47.35% over the past six months [3][19] Summary by Sections A-share and Hong Kong Innovative Drug Sector Performance - A total of 56 stocks rose and 88 stocks fell in the innovative drug sector across mainland China and Hong Kong [2] - The top three gainers were China Antibody-B (+22.79%), Yiteng Jiahe (+14.00%), and Nuocheng Jianhua (+12.24%) [2][13] - The bottom three performers were Yaojie Ankang-B (-14.58%), Shuanglu Pharmaceutical (-13.95%), and Xin Nuowei (-12.53%) [2][13] Recent Approvals and Clinical Trials - In February, four innovative drugs were approved for market in China, with no new indications approved [4][22] - In the US, one NDA was approved, with no BLA approvals reported [5][40] - No innovative drugs were approved in Europe or Japan during this period [5][29][34] Global Innovative Drug Transactions - A total of 19 significant transactions occurred globally, with four notable deals disclosed [6][43] - Key transactions included a $1.5 billion agreement between Saintgen Biotech and Genentech, and a $388 million deal between Fuhong Hanlin and Eisai [6][43] Market Data - The total market capitalization of the pharmaceutical industry is approximately 53,087.87 billion [11] - The industry P/E ratio (TTM) stands at 37.3, compared to the CSI 300's P/E ratio of 14.0 [11]